Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5816280 | 0.77 | P2RX7 (1.00) | P2RX7TRPA1SIGMAR1 | |
| SCHEMBL25415200 | 0.72 | SMN1; SMN2 (0.57) | P2RX7NPC1RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL12597163 | 0.71 | NPC1 (0.56) | P2RX7NPC1RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL3595866 | 0.71 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3595458 | 0.71 | P2RX7 (1.00) | P2RX7TRPA1SIGMAR1HDAC1HDAC6 | |
| SCHEMBL5815652 | 0.68 | P2RX7 (0.78) | P2RX7TRPA1SIGMAR1 | |
| SCHEMBL16014717 | 0.67 | SMN1; SMN2 (0.56) | P2RX7NPC1RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL11291541 | 0.67 | SMN1; SMN2 (0.56) | P2RX7NPC1RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL16014774 | 0.67 | SMN1; SMN2 (0.56) | P2RX7NPC1RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL10771614 | 0.67 | SMN1; SMN2 (0.56) | P2RX7NPC1RAB9ASMN1; SMN2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | claimed |
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885TRPA1 102/4885SIGMAR1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.